Industry Trend

Site Sections

Menu








© 2023. All Rights reserved.

Overview for AMGEN

All Data per May 26, 2023

Industry:

Drug Manufacturers—General

Last Close:

216.93 USD

Expected Dividend:

3.93 %

Payoffs per Year:

4
Business Summary
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; and Datos Health. It also has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Competitors View

Ordering

PFIZER

USA		 0.89 3.74%
4.36%		 6.07% 4.49% 1.0 0.61
-43.29%		 46.05 16.02% 48.64 1.0

ABBVIE

USA		 1.02 3.5%
4.3%		 10.17% 5.07% 1.0 3.15
-14.88%		 42.79 13.02% 12.45 2.0

ASTRAZENECA

GBR		 1.06 3.6%
2.11%		 5.97% 4.3% 0.5 16.21
-3.86%		 67.14 17.71% 38.41 3.0

SANOFI

FRA		 1.11 3.8%
3.58%		 1.59% 3.73% 1.0 0.88
-12.18%		 49.68 12.1% 59.3 4.0

CHUGAI PHARMACEUTICAL

JPN		 0.98 1.38%
2.08%		 16.13% 2.65% 1.0 3.06
-38.8%		 42.96 15.38% 77.21 5.0

MERCK & CO.

USA		 1.09 3.4%
2.67%		 5.29% 3.94% 1.0 3.67
-11.68%		 47.47 8.91% 42.19 6.0

BRISTOL-MYERS SQUIBB

USA		 0.95 2.6%
4.47%		 2.48% 2.66% 1.0 0.53
-24.44%		 34.16 17.14% 32.14 7.0

ASTELLAS PHARMA

JPN		 1.01 2.35%
2.85%		 19.78% 5.38% 1.0 1.47
-19.06%		 31.03 -2.41% 62.61 8.0

ELI LILLY AND COMPANY

USA		 1.1 2.36%
1.06%		 14.8% 4.25% 1.0 11.83
-12.71%		 45.05 7.83% 21.77 9.0

AMGEN

USA
 0.95 2.75%
3.93%		 10.11% 3.97% 1.0 1.83
-17.4%		 38.25 -3.13% 5.62 10.0

DAIICHI SANKYO

JPN		 1.07 2.05%
0.7%		 6.06% 2.46% 1.0 10.21
-17.26%		 41.99 11.62% 60.81 11.0

KYOWA HAKKO KOGYO

JPN		 0.95 1.65%
1.91%		 8.0% 2.16% 1.0 3.07
-15.61%		 44.19 3.67% 81.16 12.0

OTSUKA HOLDINGS CO., LTD.

JPN		 1.01 2.16%
1.93%		 0.0% 1.98% 1.0 0.44
-14.62%		 29.23 12.66% 72.92 13.0

ROCHE

CHE		 0.92 3.1%
3.27%		 1.69% 3.06% 1.0 0.55
-23.37%		 40.4 0.0% 36.32 14.0

GILEAD SCIENCES

USA		 1.04 3.5%
3.89%		 3.61% 3.76% 0.5 0.24
-42.43%		 36.76 3.95% 33.57 15.0

JOHNSON & JOHNSON

USA		 0.96 2.69%
3.05%		 5.9% 3.2% 1.0 0.19
-12.62%		 46.37 -0.95% 40.99 16.0

BAYER

GER		 1.06 2.96%
3.68%		 0.81% 2.81% 0.5 -0.3
-58.76%		 37.48 -6.72% 31.17 17.0

GLAXOSMITHKLINE

GBR		 1.02 6.49%
2.62%		 0.0% 5.95% -1.0 0.02
-24.56%		 47.0 -2.84% 16.79 18.0

GRIFOLS SA

ESP		 0.91 1.1%
0.0%		 -53.18% 0.2% -0.5 -0.11
-65.73%		 32.66 2.01% 38.04 19.0

Information for AMGEN

Yield Triangle

Dividend & Close

Dividend Close Div.-Yield
Year
2023 8.52 216.93 3.93
2022 7.76 262.64 2.95
2021 7.04 224.97 3.13
2020 6.40 229.92 2.78
2019 5.80 241.07 2.41
2018 5.28 190.73 2.77
2017 4.60 173.90 2.65
2016 4.00 146.21 2.74
2015 3.16 162.33 1.95
2014 2.44 159.29 1.53
2013 1.88 114.08 1.65

Fundamentals

Chart